User account
For more informaton or to schedule a product demonstration...
contact@digitalbiopharm.com
June 13, 2014 - 03:50

Parkinson's disease is second most common neurodegenerative disease. Treating Parkinson's disease is based on levodopa and two alternatives dopamine agonist (DA) and monoanime oxidase type B inhibitors (MAOBI). Prolonged use of levodopa can lead to appearance of involuntary muscle spasms and movement functions. Beside good results with DA and MAOBI, still the most widely used drug for the treatment of the Parkinson's disease is levodopa.

June 13, 2014 - 00:52

AFFiRiS AG from Viena, Austria have announced data of compound AD04 from phase II study in Alzheimer's patients. The compound AD04 has shown significant results in cognitive/functional outcome and the volume of the hippocampus during 18 months. The compound AD04 also shown an impact on behavioral and quality of life outcomes. Depend on dosage and formulation compound AD02, 24-31% of the patients showed cognitive and functional improvement and stabilization. During 18 months Hippocampusvolume could not be detected.

June 10, 2014 - 04:11

Patients with multiple myeloma relapse and develop resistance to a treatment. That's why new therapies are crucial to fight the disease and increase survival rate of patients with multiple myeloma. Novartis presented results of LBH589 (panobiostat) in combinations with bortezomib and dexamethasone showing increases of 37% in progression-free survival in comparison to the treatment of same regimen with placebo in patients with relapsed or relapsed and refractory multiple myeloma.

June 10, 2014 - 02:13

New data, announced by Novartis, showed the shrinking influence of Zykadia™ (ceritinib, previously known as LDK378) on tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). Shrinking of cancer is noticed even in patients who had received previous treatment with and ALK inhibitors and in patients with ALK and NSCLC with brain metastases. Among tested patients 58,5% showed overall response rate (ORR) on ceritinib and a median progression-free survival (PFS) of 8.2 months.